(EMAILWIRE.COM, September 18, 2018 ) The global Perfusion Systems Market is expected to reach USD 1,198.8 Million by 2021 from USD 989.4 Million in 2016, at a CAGR of 3.9%. The growth of the market can be attributed to the increasing prevalence of cardiovascular & respiratory diseases, initiatives by governments & NGOs to encourage organ donation, increasing investment in cell-based research, and developments in biologics manufacturing. The high cost of organ transplantation and organ supply-demand gap, however, are expected to hinder the growth of the market.

The Perfusion Systems Market is segmented on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion systems, and cell perfusion systems) and region.

Geographically, North America is estimated to account for the largest share of the global market, followed by Europe. The Asia-Pacific region is expected to witness the highest growth in the market during the forecast period. This growth will be particularly centered on China, Japan, and India.

The major players in the cardiopulmonary Perfusion Systems Market include Getinge AB (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), Terumo Corporation (Japan), and XENIOS AG (Germany). The major players in the ex vivo organ perfusion system market are Lifeline Scientific, Inc. (U.S.) and XVIVO Perfusion AB (Sweden), while, Repligen Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA (Germany), Harvard Bioscience, Inc. (U.S.), and ALA Scientific Instruments, Inc. (U.S.) are some of the leading players in the cell perfusion systems market.

Download Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=164273069    

Key players adopted strategies such as partnerships, collaborations, joint ventures, agreements, mergers & acquisitions, approvals, product launches, and expansions to maintain and enhance their position in the market.

Partnerships, collaborations, joint ventures, agreements, and mergers & acquisitions accounted for 28.6% of the all strategic developments from 2013 to 2016. Players adopted this strategy to strengthen their distribution networks, expand their research network, and enhance their market reach & customer base. In 2015, Getinge AB partnered with iMDsoft GmbH to integrate its data management systems into Getting’s heart-lung machines, blood/gas monitors, and heater-cooler units. Similarly, in 2015, Sorin and Cyberonic merged to form LivaNova PLC. The key players that adopted these strategies were Getinge AB, Medtronic plc, LivaNova PLC, Terumo Corporation, and XENIOS AG.

Product launches accounted for 21.9% of strategic developments in the market from 2013 to 2016. This strategy was employed by players to enhance their product portfolios. In 2015, Medtronic plc launched Affinity CP Centrifugal Blood Pump in Brazil. Similarly, LivaNova PLC launched Flextherm— heating and cooling systems in 2015. In 2016, Terumo Corporation launched the CAPIOX FX Advance oxygenator. Medtronic plc, LivaNova PLC, Lifeline Scientific, Inc., XVIVO Perfusion AB, Repligen Corporation, and Terumo Corporation were the key players who adopted this strategy.



Contact:

Mr. Shelly Singh

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: 1-888-600-6441
newsletter@marketsandmarkets.com